Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The WHO just released its third edition of the global TB mutation catalogue — the most expansive reference yet for decoding drug-resistant tuberculosis. The updated guide covers data from over 71,000 clinical isolates across 75+ countries and expands evidence for newer anti-TB drugs like pretomanid and cycloserine. It's a major step toward faster, more accurate TB diagnosis worldwide.
The World Health Organization has published the third edition of its Catalogue of Mutations in Mycobacterium tuberculosis Complex and Their Association with Drug Resistance — the most comprehensive global reference to date for interpreting genomic mutations linked to drug-resistant TB. The updated catalogue is designed to standardize how labs, surveillance programs, and diagnostic developers interpret sequencing-based drug resistance data across the globe.
This edition marks a significant leap forward from the 2023 second edition, incorporating improved bioinformatic methods, an enhanced mutation interpretation framework, and expanded evidence for newer and repurposed anti-TB medicines. It also introduces new FAQs and practical guidance to help users apply genomic results consistently in real-world settings.
By the Numbers:
Why it matters: Drug-resistant TB remains one of the world's deadliest infectious disease challenges. A more robust, globally standardized mutation catalogue means clinicians and labs can detect resistance faster and more accurately — getting patients on the right treatment sooner and strengthening TB surveillance worldwide.
